Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Merus NV  /  Merus NV forum geopend

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Merus NV OTC:MRUS.Q, NL0011606264

  • 40,450 18 apr 2024 22:00
  • -0,600 (-1,46%) Dagrange 39,980 - 41,380
  • 243.100 Gem. (3M) 547,7K

Merus NV forum geopend

1.038 Posts
Pagina: «« 1 ... 47 48 49 50 51 52 »» | Laatste | Omlaag ↓
  1. forum rang 7 Ron Kerstens 5 november 2021 17:50
    Met 110 mln erbij uit de emissie komt de cashpositie uit op bijna 450mln dollar. Ik ga er toch vanuit dat dit het laatste rondje was. Er staan nu 42,5 mln aandelen uit, 10 dollar cash per aandeel.

    Koersval valt me mee, de emissiekoers wordt in elk geval nog niet gehaald.
  4. forum rang 7 Ron Kerstens 10 november 2021 14:08
    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference (Virtual).

    The prerecorded fireside chat will be available starting on Thursday, November 18, 2021 at 8:00 am GMT/3:00 am ET on the Investors page of the Company's website and remain available for a limited time.
  9. fly like an eagle 6 december 2021 14:40
    December 6, 2021 at 6:42 AM EST
    View PDF Version
    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today released clinical data on MCLA-145 from the phase 1 trial in patients with solid tumors at the ESMO Immuno-Oncology Congress 2021 being held virtually.

    “We are encouraged by the progress we are making with MCLA-145,” said Dr. Andrew Joe, Chief Medical Officer. “Patients have been treated at 8 dose levels with preliminary evidence of antitumor activity observed, as we continue to explore MCLA-145 as monotherapy.”

    MCLA-145

    The reported data are from the phase 1 open-label, multicenter dose escalation study, of bispecific antibody MCLA-145 in patients with solid tumors. The primary objective is to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) of MCLA-145 and to determine maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE).

    Observations in the presentation include:

    As of the data cutoff date of July 14, 2021, 34 patients with advanced or metastatic solid tumors with median age of 60.5 (range 27-81) years have been treated at 8 dose levels ranging from 0.4-75mg Q2W
    Median (range) duration of treatment with MCLA 145 was approximately 6 (1–74) weeks
    Reported adverse events (AEs) have been managed with drug interruption and/or administration of steroids in some patients
    Treatment-emergent AEs (TEAEs) occurred in 33 patients (97.1%); treatment-related TEAEs occurred in 23 patients (67.6%), most commonly fatigue (n=6, 17.6%) and decreased neutrophil count (n=6, 17.6%)
    DLTs defined as within 28 days from the first infusion occurred in 4 patients (11.8%)
    Laboratory alanine transaminase/aspartate transaminase (ALT/AST) elevations of any grade were observed in 15 patients (44.1%), with grade =3 ALT/AST elevations in 6 patients (17.6%)
    Preliminary evidence of antitumor activity has been observed at doses =25 mg biweekly
    Peripheral blood shows robust T-cell activation, including activation of cytotoxic CD8+ cells and cytokines, across the 10 to 75 mg biweekly dosing range
    Further evaluation of optimal dose and efficacy in PD-L1+ tumors is planned.
    The phase 1 clinical trial of MCLA-145 consists of a dose escalation phase, followed by a planned dose expansion phase. MCLA-145 is the first drug candidate co-developed under Merus’ global collaboration and license agreement with Incyte, which permits the development and commercialization of up to 11 bispecific and monospecific antibodies from the Merus Biclonics® platform. Merus retains full rights to develop and commercialize MCLA-145, if approved, in the United States; and Incyte holds full rights to develop and commercialize MCLA-145 outside the United States.
  10. fly like an eagle 10 december 2021 14:09
    December 10, 2021 at 8:00 AM EST
    View PDF Version
    - The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met

    - The triplet combination showed clinically meaningful activity after 3 lines of anti-HER2 therapies including T-DM1

    - Validates the potential of zenocutuzumab in additional indications outside NRG1 fusions

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), presented clinical data on zenocutuzumab (Zeno) in combination with trastuzumab and vinorelbine in patients (pts) with HER2 positive/amplified (HER2+) metastatic breast cancer (MBC) who had progressed on anti-HER2 antibody drug conjugates (ADC), at the San Antonio Breast Cancer Symposium in San Antonio, Texas.

    Andrew Joe, Chief Medical Officer at Merus, said, “We are pleased to present the final analysis of the triplet Zeno combination which has demonstrated clinically meaningful activity in heavily pretreated patients with HER2+/amplified MBC. We are encouraged by Zeno’s potential to be active in indications outside NRG1 fusion cancers, opening opportunities for potential collaborations in these areas.”

    The reported data are from the completed phase 2 study, designed to explore the efficacy of a triplet combination of Zeno plus trastuzumab and vinorelbine in MBC patients (NCT03321981). Preliminary results for patients treated with the triplet regimen were presented at the American Society of Clinical Oncology 2020 Annual Meeting. The combination was observed to be well-tolerated in the run-in cohort and the cohort was expanded. The primary endpoint of the study was clinical benefit rate (CBR) at 24 weeks of 45%. Updated results from the cohort expansion are presented here:

    At the efficacy data cut-off, March 31, 2021, 39 patients, with a median age of 57 and with a median number of five prior therapies, had received the Zeno-based triplet combination, 4 of whom were ongoing. All patients had completed at least 6 months of treatment or discontinued
    37 patients with locally confirmed HER2 overexpression (IHC 3+ or IHC 2+/FISH-positive) were evaluable for antitumor activity
    The clinical benefit rate (CBR: complete response + partial response + stable disease =24 weeks) per investigator assessment was 49% (18/37 patients; 90% CI 34 - 63)
    Confirmed responses (per investigator) were reported in 10 patients, including 2 patients with complete response (CR)
    Median duration of response was 4.2 months (90% CI 2.8 - 12.4), including 2 patients with CR lasting 4.2 and 7.2+ months, and 8 patients with partial responses (PR) lasting from 2.6 to 12.4 months
    Median progression-free survival was 5.5 months (90% CI 4.1 - 5.6); 7 patients (19%) were censored. Estimated overall survival rates at 12 and 24 months were 73% and 61%, respectively
    The combination was observed to be well tolerated, with AEs primarily related to chemotherapy
    As previously reported, with completion of this phase 2 trial, Merus does not have plans to advance into a phase 3 clinical trial in metastatic breast cancer in the absence of a partner. The company continues to focus on the eNRGy trial to potentially support a BLA submission seeking a tumor agnostic indication for Zeno in patients with previously treated NRG1+ cancers.
  12. fly like an eagle 25 februari 2022 10:26
    Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
    January 25, 2022 at 4:30 PM EST
    View PDF Version
    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology.

    “Shannon will be instrumental in advancing Merus’ mission to become a commercial-stage company, further advancing the strategy for our lead clinical program, zenocutuzumab for neuregulin 1 fusion cancer and developing our commercial approach for our pipeline of innovative multispecific antibody product candidates,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. “Her leadership and depth of experience in launching products, managing partnerships, and delivering sustained performance in highly competitive oncology markets will be a great asset to our organization.”

    Ms. Campbell will join Merus as Executive Vice President & Chief Commercial Officer in February to lead the commercial strategy for the most advanced clinical candidate, zenocutuzumab (Zeno), as well as Merus’ robust pipeline of multispecific product candidates in development. This includes petosemtamab (MCLA-158), currently under investigation in second-line head and neck squamous cell carcinoma; MCLA-145, under investigation for solid tumors; and MCLA-129, under investigation for patients with lung and other solid tumors, particularly those that do not respond to EGFR inhibitors. Merus holds global rights to all four clinical candidates, apart from MCLA-129, for which Merus licensed to Betta Pharmaceuticals the exclusive right to develop and commercialize in China.

    Ms. Campbell brings over 25 years of pharmaceutical commercialization experience and joins Merus from Novartis Pharmaceuticals, where she led Novartis’s U.S. Oncology Solid Tumor Franchise and was responsible for a broad portfolio of therapies in oncology and rare diseases. Prior to Novartis, Ms. Campbell was with Bayer HealthCare Pharmaceuticals, where she was instrumental in helping to build, launch and lead Bayer’s U.S. Oncology business.

    “I am excited to join Merus at this pivotal time,” said Ms. Campbell. “The Merus pipeline of clinical-stage assets has the potential to offer meaningful benefit to patients, and I look forward to building and leading the commercial strategy for these programs.”

    Merus also announced today that Incyte (Nasdaq: INCY) has elected to opt-out of its ex-U.S. development of MCLA-145, restoring full global rights to Merus. MCLA-145 is currently enrolling a global, phase 1, open-label, single-agent clinical trial evaluating MCLA-145 in patients with solid tumors. The trial consists of a dose escalation phase, followed by a planned dose expansion phase. Merus is also planning to evaluate the combination of MCLA-145 with a PD-1 blocking antibody.

    "Regaining worldwide rights to MCLA-145 opens up new possibilities for Merus," said Dr. Lundberg. "We remain committed to continuing the development of MCLA-145 to explore the potential of this compound as monotherapy, as well as in combination, to address the high unmet medical need for patients with solid tumors. We look forward to the further progress and continued success of our other joint projects in research and development with Incyte under this collaboration.”

    Under the terms of a 2017 Collaboration and License Agreement (“Agreement”) between Merus and Incyte, Incyte received ex-U.S. rights to MCLA-145. Incyte’s opt-out of ex-U.S. rights to MCLA-145 provides Merus the exclusive right to develop and commercialize potential MCLA-145 products globally. As part of the Agreement, Incyte will continue to support the program for a limited time while ex-U.S. activities are transitioned to Merus, and Incyte will also retain a right to a residual royalty of up to 4% on sales of future commercialization of MCLA-145, if approved.

    Additionally, per the Agreement, the parties will continue to collaborate on the development and commercialization of up to ten bispecific or monospecific antibody programs. Merus also has the option to co-fund development of product candidates arising from two programs. For any program for which Merus exercises its co-development option, Merus would be responsible for 35 percent of global development costs in exchange for a 50 percent share of U.S. profits and losses and tiered royalties ranging from 6 to 10 percent on ex-U.S. sales by Incyte for these programs. Merus also has the right to elect to provide up to 50 percent of detailing activities for product candidates arising from one of these programs in the U.S.
  15. fly like an eagle 25 april 2022 17:16
    Merus Announces Publication in Nature Cancer on Petosemtamab’s (MCLA-158) Unique Mechanism of Action
    April 25, 2022 at 8:00 AM EDT
    View PDF Version
    UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced publication of a preclinical report on petosemtamab (Peto, MCLA-158: LGR5 x EGFR Biclonics®) in the journal Nature Cancer. The publication will be available at 11:00 a.m. ET today. The report describes the use of the company’s Biclonics® platform to perform a large-scale functional screen of bispecific antibodies resulting in selection of Peto, a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G protein-coupled receptor (LGR5). Peto displayed potent growth inhibition of colorectal cancer (CRC) organoids, blockade of metastasis initiation and tumor outgrowth in preclinical models of different tumor types. Peto specifically triggered EGFR degradation in organoids expressing LGR5, while showing minimal toxicity towards normal LGR5-expressing organoids.

    In October 2021, Merus reported early, interim clinical data in an ongoing trial of Peto in patients with head and neck squamous cell carcinoma (HNSCC).

    “This publication demonstrates the potential of our Biclonics® platform to generate large numbers of diverse panels of antibodies, undertake high throughput functional screening of in-format bispecifics, and identify drug candidates that possess specific biology and characteristics for therapeutic applications,” said Cecile Geuijen, Ph.D., Senior Vice President and Chief Scientific Officer. “We are encouraged by the preclinical and clinical data we have obtained to date, and look forward to the further clinical development of Peto.”

    The results published in Nature Cancer further describe Peto’s results in preclinical models of solid tumors, including the following highlights:

    Peto exhibits unique therapeutic properties such as potent growth inhibition of KRAS mutant CRC organoids, blockade of metastasis initiation, and inhibition of tumor outgrowth in preclinical models of different tumor types
    Peto shows superior growth inhibition relative to cetuximab, an EGFR inhibitor used for treatment of metastatic CRC and HNSCC, in subcutaneous xenografts generated from inoculation of C31M, a patient-derived CRC organoid bearing a KRAS G12D mutation
    Unlike cetuximab, Peto triggers EGFR internalization and degradation through LGR5
    Peto shows in vivo anti-tumor activity in other tumor types that express LGR5 such as esophageal squamous cell carcinoma, gastric carcinoma and HNSCC
    Peto is currently enrolling in a phase 1 open-label, multicenter study in patients with solid tumors. Merus is planning a clinical update for the second half of 2022.
  16. forum rang 4 Lingus 27 mei 2022 19:26
    Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
    May 26, 2022 at 5:00 PM EDT
    - Robust 34% overall response rate and 9.1 months median duration of response across multiple NRG1+ tumor types
    - Zenocutuzumab observed to be well-tolerated
    - Oral presentation with additional patient data at ASCO on June 5, 2022, 9:45 -11:15 a.m. CT
    - Investor call to discuss clinical results on Sunday, June 5 at 6:00 p.m. CT
    Lees verder: ir.merus.nl/news-releases/news-releas...

    In 2017 en 2018 kocht ik Merus op gemiddelde aankoop $24,00. In de jaren daarna was het koersverloop teleurstellend. Ik was blij dat ik op 2 maart dit jaar kon verkopen op $30,00. Daarna zakte heel biotech verder, en Merus naar $13,47. Zo laag dat ik gisteren aan kopen dacht. Het bericht gisteren en het koersverloop vanmiddag haalde me over: ik zit er weer in op $16,98. Beetje winst gemist maar er zit nu wel weer een grote ruimte naar boven.
  17. DrBob 6 juni 2022 13:40
    Ter info..
    Dit bericht was van 3/6:
    Does Merus N.V. (MRUS) Have the Potential to Rally 113% as Wall Street Analysts Expect?
    finance.yahoo.com/news/does-merus-n-v...

    En gisteren 5/6 nog meer goed nieuws:
    Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)
    finance.yahoo.com/news/merus-presents...
  19. fly like an eagle 9 augustus 2022 12:10
    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter that ended June 30, 2022 and provided a business update.

    “At the 2022 ASCO Annual Meeting, we provided an update on our lead bispecific antibody, Zeno, which demonstrated strong efficacy across multiple tumor types, clinically meaningful duration of response and a very well tolerated safety profile. We continue to believe Zeno has the potential to be both first in class and best in class for patients with NRG1 fusion cancer,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. “Additionally, we continue to make progress with our pipeline and look forward to providing an update on MCLA-129 in the second half of 2022, and Peto in the first half of 2023.”
1.038 Posts
Pagina: «« 1 ... 47 48 49 50 51 52 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!